Stockreport

MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... [Yahoo! Finance]

MaxCyte, Inc.  (MXCT) 
PDF Cell Therapy Revenue: $6.5 million, a 39% year-over-year increase. Drug Discovery Revenue: $1.6 million, a 14% year-over-year decline. Instrument Revenue: $1.8 mill [Read more]